Mainstay Medical announces € 30 million financing new capital to complete US Pivotal ReActiv8-B clinical study and advance european commercialization

- 15/02/2018

Dublin, Ireland: 15 February 2018 – Mainstay Medical International plc (Euronext Paris: MSTY.PA and ESM of the Irish Stock Exchange: MSTY.IE), a medical device company focused on bringing to market ReActiv8®, an implantable neurostimulation system to treat disabling Chronic Low Back Pain, announces today that it has raised gross proceeds of €30.1 million through the issue of 2,151,332 new ordinary shares (New Shares) to new and existing shareholders.

More info on Mainstay Medical’s website.